Chromologic LLC

Chromologic LLC, a minority-owned, American Indian-owned, and Subcontinent Asian American-owned small business based in Monrovia, California, develops advanced biomedical and medical-device technologies for federal agencies as a prime contractor (96% of recent awards) under Small Business Innovation Research and full-and-open awards. The company operates as a for-profit limited liability company and competes predominantly under total small business set-asides across SBIR and STTR programs, with occasional full-and-open civilian health-research awards.

Chromologic's capability portfolio centers on radiation medical countermeasures, portable diagnostic and oxygen-generation devices, CRISPR-based assays, microRNA biomarker development, and biomedical engineering. Representative work includes a $4.5 million definitive contract from the National Institute of Allergy and Infectious Diseases (NIAID), awarded July 2026 through June 2029, for development of radiation/nuclear medical countermeasures, biodosimetry devices, and an engineered probiotic therapeutic (LR-IFN-Beta) for gastrointestinal acute radiation syndrome mitigation, structured as cost-plus-fixed-fee with a ceiling of $4.5 million. A $1.3 million Defense Health Agency Phase II SBIR definitive contract, awarded September 2025, covers development of a ceramic membrane-based portable oxygen generator for forward surgical teams with firm fixed-price terms and ultimate completion January 2028. A $1.5 million Phase II SBIR from NIAID, awarded September 2025, funds a CRISPR-based assay for portable tropical infection diagnosis (CAPTIN-D) under firm fixed-price terms through September 2028. Chromologic also holds a $4.88 million cost-plus-fixed-fee contract from NIAID, awarded July 2023, for development of MIDOS (A MicroRNA Biodosimeter) running through June 2027.

Customer concentration reflects heavy weighting toward health-research and defense health agencies. The top five funding customers account for 76% of combined potential value: the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (1 award, $25.2 million), NIAID (15 awards, $24.1 million), Army Medical Command (19 awards, $10.7 million), Defense Health Agency (8 awards, $5.9 million), and DOD Missile Defense Agency (4 awards, $4.5 million). By award count, a different ranking emerges: Army Medical Command leads with 19 awards ($10.7 million combined potential value), followed by NIAID with 15 awards ($24.1 million combined potential value), and Defense Health Agency with 8 awards ($5.9 million combined potential value). The divergence signals that ASPR anchors a single large contract while Army Medical Command's volume reflects repeated SBIR Phase I and Phase II issuances across multiple research topics.

Chromologic's federal awards span 111 total primes and subs across 32 agencies with combined potential value of $92.9 million, of which $87.7 million (94%) has been obligated. Recent activity shows eight awards in 2022, declining to seven annually in 2023, 2024, and 2025, with two awards recorded in 2026. The award pipeline faces a recompete cliff of $11.3 million in combined potential value across eight awards reaching ultimate completion within the next twenty-four months. Top NAICS categories reflect the vendor's R&D posture: Research and Development in the Physical, Engineering, and Life Sciences (40 awards), with substantial biotechnology work (7 awards). Top PSCs align similarly: R&D—Medical: Other (Basic Research) at 19 awards and Health R&D Services at 14 awards.

Service Contract Inventory captures $4 million in invoiced revenue across FY2022–FY2024 on SCI-reportable prime contracts above the $150,000 threshold. FY2022 showed $2.1 million across 7.8 FTEs; FY2023 reported $1.9 million across 5.2 FTEs; FY2024 carried no SCI invoicing. On federal services contracts captured in SCI, government-paid median hourly rates ran approximately $126/hr, with senior labor pricing reaching $300/hr at the 90th percentile. SCI is a partial federal view and excludes goods, products, classified work, and non-federal revenue; these dollar and FTE figures do not represent total company revenue or workforce. Chromologic does not engage subcontractors on SCI-reportable work; subcontract activity appears limited to two sub-awards to Alpha Omega Biotechnology Services LLC in May 2025 for manufacture of probiotic therapeutics and one grant sub-award under UCLA for miRNA biomarker research.